Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans.
about
Is GLP-1 a hormone: Whether and When?New insight into the mechanisms underlying the function of the incretin hormone glucagon-like peptide-1 in pancreatic β-cells: the involvement of the Wnt signaling pathway effector β-cateninRelationship between gut hormones and glucose homeostasis after bariatric surgeryMolecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor InternalisationMeal-anticipatory glucagon-like peptide-1 secretion in rats.Do Incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: What are the evidence?Glucagon-like peptide-1 and glucose-dependent insulinotropic peptide: effects alone and in combination on insulin secretion and glucose disappearance in mice.Expression of human globular adiponectin-glucagon-like peptide-1 analog fusion protein and its assay of glucose-lowering effect in vivoGlucagon-like peptide-1 (GLP-1) analogs: recent advances, new possibilities, and therapeutic implications.What if gut hormones aren't really hormones: DPP-4 inhibition and local action of GLP-1 in the gastrointestinal tractGlucose effectiveness in obese children: relation to degree of obesity and dysglycemia.β-Cell Sensitivity to GLP-1 in Healthy Humans Is Variable and Proportional to Insulin Sensitivity.Gut peptides in the treatment of diabetes mellitus.Defects in GLP-1 response to an oral challenge do not play a significant role in the pathogenesis of prediabetes.Plasticity of the beta cell insulin secretory competence: preparing the pancreatic beta cell for the next meal.Effects of increasing doses of glucagon-like peptide-1 on insulin-releasing phases during intravenous glucose administration in mice.The incretin effect and its potentiation by glucagon-like peptide 1-based therapies: a revolution in diabetes management.Cardiovascular biology of the incretin system.The incretin effect in obese adolescents with and without type 2 diabetes: impaired or intact?Central control of body weight and appetite.Direct effects of exendin-(9,39) and GLP-1-(9,36)amide on insulin action, β-cell function, and glucose metabolism in nondiabetic subjects.Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptidesEntero-insular axis and postprandial insulin differences in African American and European American children.Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetesThe structure and function of the glucagon-like peptide-1 receptor and its ligandsGLP-1 based therapies: differential effects on fasting and postprandial glucose.Cardiovascular effects of incretin-based therapies.The therapeutic potential of GPR119 agonists for type 2 diabetes.The place of GLP-1-based therapy in diabetes management: differences between DPP-4 inhibitors and GLP-1 receptor agonists.Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions.Glicentin-related pancreatic polypeptide inhibits glucose-stimulated insulin secretion from the isolated pancreas of adult male ratsHepatic functions of GLP-1 and its based drugs: current disputes and perspectives.GLP-1 receptor independent pathways: emerging beneficial effects of GLP-1 breakdown products.Advancing therapeutic discovery through phenotypic screening of the extracellular proteome using hydrodynamic intravascular injection.GLP-1(28-36) improves β-cell mass and glucose disposal in streptozotocin-induced diabetic mice and activates cAMP/PKA/β-catenin signaling in β-cells in vitro.Possible involvement of GLP-1(9-36) in the regional haemodynamic effects of GLP-1(7-36) in conscious rats.Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesisRETRACTED: Therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment.Characterization of protein release from poly(ethylene glycol) hydrogels with crosslink density gradients.Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.
P2860
Q26749196-CC0F5138-39CF-475A-9FDA-926318E0DD49Q26823824-40BE98CE-EDC5-45A5-8DE1-283FA436EB11Q27022123-63BCE6BC-DF3D-4C4A-BBB5-CB4CBC7DB9EAQ28551517-6A4E97E3-F8AE-4C9C-9DCD-FF6A502EEE2AQ33634407-E720D7D2-3F1D-4692-B71E-4944DFEFE4E9Q33789529-6E11B290-CB28-444A-8E27-D76B4E409521Q33800196-EA66BC4B-3C2D-4103-B34B-D9A2DD2BD7D5Q34648270-FDC6B483-3A89-4CB2-B0D5-6FC7C2369B31Q35087846-07B39C50-078F-4441-A546-61AA6F30D0BAQ35110830-062414AC-795B-49DD-8914-45E42DD63855Q35207924-877AD2D2-6D7E-4884-A316-A0FBAFAAD4DBQ35680897-D4A3DD74-5D4F-45A1-AA98-2F88AFAF320AQ35688209-D109B78D-21DD-4EE1-B4A5-3F8584733DFDQ35744498-56E40F6B-EB9A-4836-9C11-32BD7A3B3FDBQ35794504-D77D2905-45D7-4482-8304-A62AE1CF2CB2Q35801801-3F82D884-0939-4136-BA1B-AE8D30EAFE41Q36187070-CEEF98E5-BCB3-4CFC-AA40-37F4F649F641Q36484283-5616E2C5-39E5-489F-BBA4-1A1A3DEDC6C7Q36902183-0B8CD835-41C8-4640-9DE8-254D19B730D7Q36979763-FD370A4A-16EC-4FDD-86D3-BB86ED09E976Q37031078-D643C25C-CFA8-47E4-9905-4D581FD16EAFQ37212333-945AC0C3-B69C-4C4E-85F0-96C77E84A22BQ37445535-2CDDD557-701F-41AB-A48C-B8087EEAB394Q37857695-13422452-648F-4962-A857-8F4906A6906DQ37939244-6901BAE7-0F28-4535-B0FD-6537940135BAQ37974712-10DA0388-B833-45AD-BFA4-009AA078A0DBQ37977336-1DCA485C-D4BE-4E5E-BE02-0D0E3B9FCDEAQ37980173-2C8F5314-4247-4D66-9C5D-BEC8E4F0555DQ38088195-BAAD5D1F-DE56-4591-AE5E-0B89C21B3D41Q38264456-0293DE04-B797-4B78-B035-BCC4BDE58E03Q38565583-1276A515-DC2F-4ACC-A30C-995721CD8016Q38923365-779D4BD5-639F-4B73-B461-21ACB06D7DD4Q39063954-9691B660-D856-4ED0-91A5-A68751A5CF01Q39117888-A20D4F78-ED2E-42DA-AAC9-5D323CF3DFACQ39168828-AD3C0DBB-77A4-429A-8988-774C61FAD72DQ41809232-B23327FB-1028-4A9B-A46C-F4EF495D9077Q42022343-3D3518B4-B594-430F-B60F-599F3E248664Q42105494-10350C51-5174-4DDC-8FB6-EAAA8B284AB0Q42824467-B22A7D33-8B89-4508-882C-421BFA220785Q43194107-557D1556-5353-4042-82EE-150096E3096D
P2860
Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans.
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Effects of GLP-1-(7-36)NH2, GL ...... n secretion in healthy humans.
@ast
Effects of GLP-1-(7-36)NH2, GL ...... n secretion in healthy humans.
@en
type
label
Effects of GLP-1-(7-36)NH2, GL ...... n secretion in healthy humans.
@ast
Effects of GLP-1-(7-36)NH2, GL ...... n secretion in healthy humans.
@en
prefLabel
Effects of GLP-1-(7-36)NH2, GL ...... n secretion in healthy humans.
@ast
Effects of GLP-1-(7-36)NH2, GL ...... n secretion in healthy humans.
@en
P2093
P356
P1476
Effects of GLP-1-(7-36)NH2, GL ...... n secretion in healthy humans.
@en
P2093
Bradley D Fuller
Breay W Paty
David A D'Alessio
Ronald L Prigeon
Torsten P Vahl
P304
P356
10.1210/JC.2002-021479
P407
P577
2003-04-01T00:00:00Z